1. Home
  2. CRON vs GYRE Comparison

CRON vs GYRE Comparison

Compare CRON & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRON
  • GYRE
  • Stock Information
  • Founded
  • CRON N/A
  • GYRE 2002
  • Country
  • CRON Canada
  • GYRE United States
  • Employees
  • CRON N/A
  • GYRE N/A
  • Industry
  • CRON Medicinal Chemicals and Botanical Products
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRON Health Care
  • GYRE Health Care
  • Exchange
  • CRON Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • CRON 809.4M
  • GYRE 897.1M
  • IPO Year
  • CRON N/A
  • GYRE N/A
  • Fundamental
  • Price
  • CRON $2.37
  • GYRE $8.14
  • Analyst Decision
  • CRON
  • GYRE
  • Analyst Count
  • CRON 0
  • GYRE 0
  • Target Price
  • CRON N/A
  • GYRE N/A
  • AVG Volume (30 Days)
  • CRON 2.7M
  • GYRE 79.7K
  • Earning Date
  • CRON 08-07-2025
  • GYRE 08-11-2025
  • Dividend Yield
  • CRON N/A
  • GYRE N/A
  • EPS Growth
  • CRON N/A
  • GYRE N/A
  • EPS
  • CRON 0.05
  • GYRE 0.02
  • Revenue
  • CRON $130,282,000.00
  • GYRE $102,189,000.00
  • Revenue This Year
  • CRON $27.65
  • GYRE $21.04
  • Revenue Next Year
  • CRON $5.63
  • GYRE $89.64
  • P/E Ratio
  • CRON $49.36
  • GYRE $177.50
  • Revenue Growth
  • CRON 28.01
  • GYRE N/A
  • 52 Week Low
  • CRON $1.60
  • GYRE $6.11
  • 52 Week High
  • CRON $2.77
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • CRON 58.17
  • GYRE 59.57
  • Support Level
  • CRON $1.93
  • GYRE $6.62
  • Resistance Level
  • CRON $2.77
  • GYRE $8.30
  • Average True Range (ATR)
  • CRON 0.13
  • GYRE 0.45
  • MACD
  • CRON 0.04
  • GYRE 0.16
  • Stochastic Oscillator
  • CRON 52.66
  • GYRE 90.75

About CRON Cronos Group Inc. Common Share

Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: